These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16888847)

  • 41. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 43. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 44. Activated protein C: beyond 28 days.
    Manocha S; Walley KR
    Crit Care Med; 2004 Nov; 32(11):2348-9. PubMed ID: 15640656
    [No Abstract]   [Full Text] [Related]  

  • 45. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
    Doig CJ; Laupland KB; Zygun DA; Manns BJ
    Expert Opin Pharmacother; 2003 Oct; 4(10):1789-99. PubMed ID: 14521488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 47. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 48. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 50. Treating sepsis.
    Wenzel RP
    N Engl J Med; 2002 Sep; 347(13):966-7. PubMed ID: 12324551
    [No Abstract]   [Full Text] [Related]  

  • 51. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

  • 52. [Sepsis in the surgical setting: indication for activated C protein].
    Payen DM; Matéo J
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():40-2. PubMed ID: 15359942
    [No Abstract]   [Full Text] [Related]  

  • 53. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 54. Should we treat severe sepsis with activated protein C?
    Mackillop A
    Hosp Med; 2003 May; 64(5):316. PubMed ID: 12789748
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
    Weintraub J; Satterwhite T; Allo M
    Burns; 2006 Sep; 32(6):783-7. PubMed ID: 16879921
    [No Abstract]   [Full Text] [Related]  

  • 56. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 57. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 58. Management of sepsis.
    Mackenzie AF; Bartelink AK
    N Engl J Med; 2007 Mar; 356(11):1179; author reply 1181-2. PubMed ID: 17361493
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 60. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.